Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
 Coger: Distributeur de reactifs de laboratoire
		
					Coger: Distributeur de reactifs de laboratoire			
        	 
            AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
| 
                            Ajouter au panier
                            
                         Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:  | 
| 
                            Stock épuisé.
                            
                         
                            En rupture de stock
                         | 
| 
                            Quantité minimum d'achat
                            
                         
                            La quantité minimum d'achat n'est pas atteinte
                         | 
 
    
	  
	
	
    
    photos non contractuelles
Product description: Protein. The extracellular domain of human IL-15 (aa 49-162) is fused to a His-tag. Source: E. coli. Endotoxin content: <0.1EU/µg protein (LAL test; Lonza). Lyophilized from 0.2µm-filtered solution in PBS. Purity: >95% (SDS-PAGE). Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Ralpha, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.
| 
					Alerte
					
				 Veuillez saisir les champs obligatoires! |